177 related articles for article (PubMed ID: 17172161)
1. Pharmacological prerequisites for PET ligands and practical issues in preclinical PET research.
Ametamey SM; Honer M
Ernst Schering Res Found Workshop; 2007; (62):317-27. PubMed ID: 17172161
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceutical pharmacokinetics in animals: critical considerations.
Giron MC
Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):359-64. PubMed ID: 19834444
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
[TBL] [Abstract][Full Text] [Related]
4. Radioligand development for molecular imaging of the central nervous system with positron emission tomography.
Honer M; Gobbi L; Martarello L; Comley RA
Drug Discov Today; 2014 Dec; 19(12):1936-44. PubMed ID: 25173703
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
6. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V
ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography: ligand imaging.
Moghbel M; Newberg A; Alavi A
Handb Clin Neurol; 2016; 135():229-240. PubMed ID: 27432668
[TBL] [Abstract][Full Text] [Related]
8. Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [
Eberl S; Katsifis A; Peyronneau MA; Wen L; Henderson D; Loc'h C; Greguric I; Verschuer J; Pham T; Lam P; Mattner F; Mohamed A; Fulham MJ
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):296-307. PubMed ID: 27699720
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 and radiopharmaceutical metabolism.
Giron MC; Portolan S; Bin A; Mazzi U; Cutler CS
Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):254-66. PubMed ID: 18475251
[TBL] [Abstract][Full Text] [Related]
10. Applications of LC-MS in PET radioligand development and metabolic elucidation.
Ma Y; Kiesewetter DO; Lang L; Gu D; Chen X
Curr Drug Metab; 2010 Jul; 11(6):483-93. PubMed ID: 20540692
[TBL] [Abstract][Full Text] [Related]
11. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain.
Horti AG; Villemagne VL
Curr Pharm Des; 2006; 12(30):3877-900. PubMed ID: 17073685
[TBL] [Abstract][Full Text] [Related]
12. PET tracers for serotonin receptors and their applications.
Kumar JS; Mann JJ
Cent Nerv Syst Agents Med Chem; 2014; 14(2):96-112. PubMed ID: 25360773
[TBL] [Abstract][Full Text] [Related]
13. [
Liow JS; Morse CL; Lu S; Frankland M; Tye GL; Zoghbi SS; Gladding RL; Shaik AB; Innis RB; Newman AH; Pike VW
Molecules; 2018 Oct; 23(11):. PubMed ID: 30360553
[TBL] [Abstract][Full Text] [Related]
14. Radiotracer development in psychiatry.
Pimlott SL
Nucl Med Commun; 2005 Mar; 26(3):183-8. PubMed ID: 15722898
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.
Andrés JI; De Angelis M; Alcázar J; Celen S; Bormans G
Curr Top Med Chem; 2012; 12(11):1224-36. PubMed ID: 22571785
[TBL] [Abstract][Full Text] [Related]
16. [PET imaging for better understanding of normal and pathological neurotransmission].
Zimmer L
Biol Aujourdhui; 2019; 213(3-4):109-120. PubMed ID: 31829931
[TBL] [Abstract][Full Text] [Related]
17. (R)-[
Berroterán-Infante N; Kalina T; Fetty L; Janisch V; Velasco R; Vraka C; Hacker M; Haug AR; Pallitsch K; Wadsak W; Mitterhauser M
Eur J Med Chem; 2019 Aug; 176():410-418. PubMed ID: 31125895
[TBL] [Abstract][Full Text] [Related]
18. Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.
Spinelli F; Mu L; Ametamey SM
J Labelled Comp Radiopharm; 2018 Mar; 61(3):299-308. PubMed ID: 29110331
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Characterization of Selected Fluorine-18 Labeled Radioligands for PET Imaging of the Dopamine D3 Receptor.
Nebel N; Maschauer S; Kuwert T; Hocke C; Prante O
Molecules; 2016 Aug; 21(9):. PubMed ID: 27589704
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Research Highlighting Contemporary Targeting Mechanisms of Radiolabelled Compounds for PET Based Infection Imaging.
Kleynhans J; Sathekge MM; Ebenhan T
Semin Nucl Med; 2023 Sep; 53(5):630-643. PubMed ID: 37012169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
